Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized trial of Taplucainium Inhalation Powder in refractory or unexplained chronic cough
2024-515026-86-00Phase 2Completed
- Sponsor
- Nocion Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in refractory chronic cough (RCC) comparing Taplucainium Inhalation Powder with Placebo inhalation powder (2 arms). Primary endpoint: Change in 24-hour coughs per hour from baseline to Day 28. Started Nov 2024; status: completed.
02
Drugs
taplucainium chloride
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on 2024-515026-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515026-86-00.